As in the entire cohort of NPC patients, heterozygous CT for FAS −690 as compared to homozygous T showed a marginal but significantly higher risk of death univariately in the subpopulation of NPC patients treated with primary concomitant chemotherapy and radiotherapy (HR = 2.27, 95% CI: 1.00–5.18, p = 0.051), which was not retained upon adjustment for age and stage (HR = 1.32, 95% CI: 0.50–3.44, p = 0.58). The gene discussed is FAS; the disease is nasopharyngeal carcinoma.